Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03501368 · ClinicalTrials.gov registry record · Phase 1
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03501368 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 27 participants.
The verdict
NCT03501368, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.
Interventions
- DRUG Trametinib
- DRUG Ceritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03501368
The ClinicalTrials.gov registry entry for NCT03501368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trametinib is the first listed.
NCT03501368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03501368 about?
NCT03501368 is a clinical study titled "Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma". The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.
What is the current status of trial NCT03501368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-06-27. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT03501368?
The interventions under investigation include: Trametinib (DRUG), Ceritinib (DRUG).
Who is sponsoring clinical trial NCT03501368?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.